To include your compound in the COVID-19 Resource Center, submit it here.

Lucentis ranibizumab: Phase Ib/II

Preliminary data from an extension of an open-label U.S. Phase Ib/II study in 64 patients showed that the average improvement from baseline in visual acuity at day 98

Read the full 281 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE